| Título : |
Update of hepatitis C in Colombia |
| Tipo de documento : |
documento electrónico |
| Autores : |
Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Juan Carlos Restrepo Gutiérrez, ; Óscar Mauricio Santos Sánchez, |
| Fecha de publicación : |
2018 |
| Títulos uniformes : |
Current Tropical Medicine Reports
|
| Dimensiones : |
PDF |
| Idioma : |
Inglés (eng) |
| Palabras clave : |
Hepatitis C HCV Colombia South America Direct-acting antiviral DAA |
| Resumen : |
Purpose of Review The goal is to describe the epidemiology, disease burden and detection, available therapies, and current challenges to access care for people with chronic hepatitis C infection in Colombia. Recent Findings There are no detailed statistics about the prevalence of HCVin Colombia; nonetheless, majority of patients with hepatitis C are infected with genotype 1 and having received blood products before 1996 represents the main risk factor. The use of intravenous drugs has started to be recognized as a population at risk that is in increment. Direct-acting antivirals became available in 2016 in Colombia thanks to a centralized purchase program with the Pan American Health Organization. Summary There are well-established guidelines for the use of available antivirals for all disease stages and genotypes and sustained virologic response (SVR) rates are 95 to 100%. Underdiagnosis, access and linkage to care, and disease stigmatization have contributed to a low number of patients that have actually completed their therapy. |
| Mención de responsabilidad : |
Federico Hinestrosa, Juan Ignacio Marín, Octavio Muñoz Maya, Oscar Santos & Juan Carlos Restrepo |
| Referencia : |
Curr Trop Med Rep (2018) 5: 133 |
| DOI (Digital Object Identifier) : |
10.1007/s40475-018-0147-5 |
| En línea : |
https://link.springer.com/article/10.1007/s40475-018-0147-5 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3423 |
Update of hepatitis C in Colombia [documento electrónico] / Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Juan Carlos Restrepo Gutiérrez, ; Óscar Mauricio Santos Sánchez, . - 2018 . - ; PDF. Obra : Current Tropical Medicine ReportsIdioma : Inglés ( eng) | Palabras clave : |
Hepatitis C HCV Colombia South America Direct-acting antiviral DAA |
| Resumen : |
Purpose of Review The goal is to describe the epidemiology, disease burden and detection, available therapies, and current challenges to access care for people with chronic hepatitis C infection in Colombia. Recent Findings There are no detailed statistics about the prevalence of HCVin Colombia; nonetheless, majority of patients with hepatitis C are infected with genotype 1 and having received blood products before 1996 represents the main risk factor. The use of intravenous drugs has started to be recognized as a population at risk that is in increment. Direct-acting antivirals became available in 2016 in Colombia thanks to a centralized purchase program with the Pan American Health Organization. Summary There are well-established guidelines for the use of available antivirals for all disease stages and genotypes and sustained virologic response (SVR) rates are 95 to 100%. Underdiagnosis, access and linkage to care, and disease stigmatization have contributed to a low number of patients that have actually completed their therapy. |
| Mención de responsabilidad : |
Federico Hinestrosa, Juan Ignacio Marín, Octavio Muñoz Maya, Oscar Santos & Juan Carlos Restrepo |
| Referencia : |
Curr Trop Med Rep (2018) 5: 133 |
| DOI (Digital Object Identifier) : |
10.1007/s40475-018-0147-5 |
| En línea : |
https://link.springer.com/article/10.1007/s40475-018-0147-5 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3423 |
|  |
Inicio
Update of hepatitis C in Colombia
